Skip to main content
. 2021 Oct 5;9(8):903–909. doi: 10.1002/ueg2.12150

FIGURE 2.

FIGURE 2

Care paths for non‐alcoholic fatty liver disease (NAFLD): work in progress. *Exclusion of excessive alcohol use and chronic liver diseases (CLD): hepatitis B, hepatitis C, autoimmune hepatitis, and hemochromatosis. CAP, continued attenuation parameter; ELF, Enhanced Liver Fibrosis; FIB‐4, Fibrosis‐4; GLP1RA, glucagon‐like peptide‐1 receptor agonists; LSM, liver stiffness measurement; T2DM, type 2 diabetes mellitus; VCTE, vibration controlled transient elastography